1Kessler RC, Mcgonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM- Ⅲ -R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry, 1994, 51(1) : 8.
2Tohen M, Goodwin FK. Epidemiology of bipolar disorder. Psychiatric Epidemiology, 1995, 22(suppl 2) :301.
3Frye MA, Ketter TA, Altshuler LL, et al. Clozapine in bipolar disorder:treatment implications for other atypical antipsychotics. J Affective Disorder, 1998, 48(2-3):91.
4Ghaemi SN, Sachs GS. Longterm risperidone treatment in bipolar disorder: 6 month follow up. Int Clin Psychopharmacol, 1997, 12(6):333.
5Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997, 154(4):466.
6Mcelroy SL, Frye MA, Denikoff KD, et al. Olanzapine in treatment-resistant bipolar disorder. J Affect Disord, 1998, 49(2) : 119.
7Tollefson GD, Sanger TM, Lu MK, et al. Depressive signs and symptom in schizophrenia aprospective blinded trial of olanzapine and haloperidol.Arch Gen Psychiatry, 1998, 55(4) :250.
8Tollefson GD, Sanger TM, Beasley CM, et al. Double-blind, controlled comparision of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depression symptoms accompanying schizophrenia.Bio Psychiat Psychiatry Anxious, 1998, 43(11) : 803.
